Genmab — November 2025

[gdn55]

Novo nede med ca. 3,5 Ambu 18 Zeeland 3,5 Genmab 2,5.

[E_L]

Genmab A/S is set to announce its Q3 2025 earnings on November 6, 2025, with analysts expecting earnings of $0.47 per share and revenue of $975.4 million https://www.marketbeat.com/instant-alerts/genmab-as-gmab-expected-to-announce-quarterly-earnings-on-thursday-2025-10-30/

[E_L]

Genmab AS (GMAB, Financial) is set to release its Q3 2025 earnings on Nov 6, 2025. The consensus estimate for Q3 2025 revenue is $986.99 million, and the earnings are expected to come in at $0.46 per share. https://www.gurufocus.com/news/3185679/genmab-as-gmab-q3-2025-earnings-report-preview-what-to-look-for

[E_L]

seekingalpha: Genmab (GMAB) is scheduled to announce Q3 earnings results on Thursday, November 6th, before market open. The consensus EPS Estimate is $0.45 and the consensus revenue estimate is $983.65M.

[Pensionisten]

Regnskab vel først efter markedet i DK er lukket - oplyst efter kl. 17.00 - som sædvanligt.

[Raun]

Flot dag i US - et luk lige i underkanten af 1900 under pæn omsætning

[bikube]

Da jeg så det, måtte jeg lige taste en gang mere på regneren - den siger 1897,4.

[transalp]

Go morgen..

[E_L]

so Novo confirmed yesterday they also submitted an appliction for approval of denecimig / Mim8 to EMA in september

[E_L]

From lab coat to Lifestar: Jan van de Winkel shares his success story
Before Genmab's co-founder and CEO collects his Lifetime Achievement Award this November, BioXconomy caught up with him for an exclusive chat about his remarkable journey. https://www.bioxconomy.com/partnering/from-lab-coat-to-lifestar-jan-van-de-winkel-shares-his-success-story

[Raun]

Nøj, hvor er DK træls ved aktien for tiden. - Efter det store fald ovenpå Merus usikkerheden, så må aktien på ingen måder komme over 1900 og hvis kursen nærmer sig, så bliver den stille og roligt pillet ned igen - det er godt nok set nogle gange nu

[StockBull]

Ligner en normal retracement og ser ud til bunden i 1818 holder, Retracements på daggrafen tager tid. Target 2150 slut November

[Raun]

Håber du får ret @Stockbull

[E_L]

New Ph3 trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy (RAINFOL-04) https://clinicaltrials.gov/study/NCT07225270

[ProinvestorNEWS]

Genmab Announces Financial Results for the Nine Months of 2025 https://proinvestor.com/investornyt/1380034/genmab-announces-financial-results-for-the-nine-months-of-2025

[Stroka]

"Operating profit was $1,007 million in the first nine months of 2025 compared to $662 million in the first nine months of 2024".

[Vitus]

Så falder Genmab i USA -:(

[Sukkeralf]

GEN1042 lagt halvt i graven

[Sukkeralf]

Skuffende at 4-1 bb ikke kaster mere af sig i forhold til det omfattende arbejde der er lagt i dette target - og de udmeldinger der er kommet fra Jan undervejs.

[Solsen]

Vel egentlig god mening i at lægge 1042 i head and neck i graven, når man har peto i pipelinen. Spændende om acasunlimab kan holde data til december.